<DOC>
	<DOCNO>NCT00377065</DOCNO>
	<brief_summary>This treatment use study provide early access MK0518 treatment HIV-1 infection patient limit treatment option due virological failure , resistance , intolerance multiple antiretroviral regimen . Enrollment study patient driven . Investigators proactively assign . There target sample size duration study indefinite . For information enroll study , see link .</brief_summary>
	<brief_title>Early Access MK0518 Combination With Optimized Background Antiretroviral Therapy ( 0518-023 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV positive patient limited treatment option document resistance Patient previously MK0518 therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>